 |
|
|
 |
|
Myeloma Drug Works Better at Lower Dose
|
 |  |  |  | Related Healthscout Videos |  |
|
Page: << Prev | 1 | 2 | 3 Streicher stressed that the findings remain preliminary, however.
"We don't know what it will look like at two years," he said. "It's possible that we'll find out that the benefits continue for a long time, or that something else needs to be done somewhere down the line if patients relapse. Those are important questions that still need to be answered."
Lichtenfeld called the trial's success "all part of the targeted therapy story," which he said is revolutionizing cancer care.
Text Continues Below

But he also warned that current funding shortfalls at public health institutions such as the NCI -- which support and organize many of these types of clinical trials -- threaten these types of advances.
"We are understanding myeloma better and we are able to apply these drugs," Lichtenfeld said. "But if we do not continue to support these types of activities, we stand a chance of losing our progress."
More information
There's more on myeloma at the American Cancer Society.
Page: << Prev | 1 | 2 | 3
|
Copyright © 2007 ScoutNews, LLC. All rights reserved.
Last updated 4/6/2007
|
 |

SOURCES: Len Lichtenfeld, M.D., deputy chief medical officer, American Cancer Society, Atlanta; Howard Streicher, M.D., senior investigator, U.S. National Cancer Institute, Bethesda, Md.; April 4, 2007, prepared statement, U.S. National Cancer Institute
|